logo-loader
Humanigen Inc

Humanigen new research shows encouraging results for cancer treatment using Car-T

Humanigen (OTCMKTS:HGEN) CEO Cameron Durrant joined Steve Darling from Proactive Investors in Los Angeles at the LD Micro show to provide details about their latest research regarding the use of Car-T therapy in the treatment of certain blood cancers. That research was just published in the digital version if Blood Magazine. 

Quick facts: Humanigen Inc

Price: $0.82

Market: OTCQB
Market Cap: $92.48 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Humanigen Inc named herein, including the promotion by the Company of Humanigen Inc in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Humanigen inks licensing agreement with the University of Zurich to...

Humanigen Inc (OTCMKTS:HGEN) CEO Cameron Durrant tells Proactive Investors the California-based company has a new tool in its box to prevent graft-versus-host disease when treating patients with leukemia and other blood cancers. Durrant says Humanigen has received an exclusive licensing...

on 07/22/2019

2 min read